246 related articles for article (PubMed ID: 32963047)
21. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
Namas R; Tashkin DP; Furst DE; Wilhalme H; Tseng CH; Roth MD; Kafaja S; Volkmann E; Clements PJ; Khanna D;
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):439-444. PubMed ID: 28544580
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Spiera R; Kuwana M; Khanna D; Hummers L; Frech TM; Stevens W; Matucci-Cerinic M; Kafaja S; Distler O; Jun JB; Levy Y; Leszcyzński P; Gordon J; Steen V; Lee EB; Jankowski T; Litinsky I; Chung L; Hsu V; Mayes M; Sandorfi N; Simms RW; Finzel S; de Vries-Bouwstra J; Constantine S; Dgetluck N; Dinh Q; Bloom BJ; Furst DE; White B; Denton CP;
Arthritis Rheumatol; 2023 Sep; 75(9):1608-1618. PubMed ID: 37098795
[TBL] [Abstract][Full Text] [Related]
23. A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.
Spiera R; Khanna D; Kuwana M; Furst DE; Frech TM; Hummers L; Stevens W; Matucci-Cerinic M; Baron M; Distler O; Dgetluck N; Bloom BJ; Dinh Q; White B; Denton CP
Clin Exp Rheumatol; 2021; 39 Suppl 131(4):124-133. PubMed ID: 34323681
[TBL] [Abstract][Full Text] [Related]
24. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
[TBL] [Abstract][Full Text] [Related]
25. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
Herrick AL; Pan X; Peytrignet S; Lunt M; Hesselstrand R; Mouthon L; Silman A; Brown E; Czirják L; Distler JHW; Distler O; Fligelstone K; Gregory WJ; Ochiel R; Vonk M; Ancuţa C; Ong VH; Farge D; Hudson M; Matucci-Cerinic M; Balbir-Gurman A; Midtvedt Ø; Jordan AC; Jobanputra P; Stevens W; Moinzadeh P; Hall FC; Agard C; Anderson ME; Diot E; Madhok R; Akil M; Buch MH; Chung L; Damjanov N; Gunawardena H; Lanyon P; Ahmad Y; Chakravarty K; Jacobsen S; MacGregor AJ; McHugh N; Müller-Ladner U; Riemekasten G; Becker M; Roddy J; Carreira PE; Fauchais AL; Hachulla E; Hamilton J; İnanç M; McLaren JS; van Laar JM; Pathare S; Proudman S; Rudin A; Sahhar J; Coppere B; Serratrice C; Sheeran T; Veale DJ; Grange C; Trad GS; Denton CP
Ann Rheum Dis; 2017 Jul; 76(7):1207-1218. PubMed ID: 28188239
[TBL] [Abstract][Full Text] [Related]
26. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
Denton CP; Merkel PA; Furst DE; Khanna D; Emery P; Hsu VM; Silliman N; Streisand J; Powell J; Akesson A; Coppock J; Hoogen Fv; Herrick A; Mayes MD; Veale D; Haas J; Ledbetter S; Korn JH; Black CM; Seibold JR; ;
Arthritis Rheum; 2007 Jan; 56(1):323-33. PubMed ID: 17195236
[TBL] [Abstract][Full Text] [Related]
27. Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review.
Fernández-Lázaro D; Iglesias-Lázaro M; Garrosa E; Rodríguez-García S; Jerves Donoso D; Gutiérrez-Abejón E; Jorge-Finnigan C
Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837449
[TBL] [Abstract][Full Text] [Related]
28. A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS).
Griffiths-Jones DJ; Garcia YS; Ryder WD; Pauling JD; Hall F; Lanyon P; Bhat S; Douglas K; Gunawardena H; Akil M; Anderson M; Griffiths B; Del Galdo F; Youssef H; Madhok R; Arthurs B; Buch M; Fligelstone K; Zubair M; Mason JC; Denton CP; Herrick AL
Rheumatology (Oxford); 2023 Sep; 62(9):3133-3138. PubMed ID: 36637209
[TBL] [Abstract][Full Text] [Related]
29. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis.
Poelman CL; Hummers LK; Wigley FM; Anderson C; Boin F; Shah AA
J Rheumatol; 2015 Feb; 42(2):236-42. PubMed ID: 25433527
[TBL] [Abstract][Full Text] [Related]
30. Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis.
Mendoza FA; Lee-Ching C; Jimenez SA
Semin Arthritis Rheum; 2020 Feb; 50(1):135-139. PubMed ID: 31311679
[TBL] [Abstract][Full Text] [Related]
31. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.
Spiera RF; Gordon JK; Mersten JN; Magro CM; Mehta M; Wildman HF; Kloiber S; Kirou KA; Lyman S; Crow MK
Ann Rheum Dis; 2011 Jun; 70(6):1003-9. PubMed ID: 21398330
[TBL] [Abstract][Full Text] [Related]
32. Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.
Stifano G; Sornasse T; Rice LM; Na L; Chen-Harris H; Khanna D; Jahreis A; Zhang Y; Siegel J; Lafyatis R
Arthritis Rheumatol; 2018 Jun; 70(6):912-919. PubMed ID: 29858547
[TBL] [Abstract][Full Text] [Related]
33. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.
Su TI; Khanna D; Furst DE; Danovitch G; Burger C; Maranian P; Clements PJ
Arthritis Rheum; 2009 Dec; 60(12):3821-30. PubMed ID: 19950289
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
[TBL] [Abstract][Full Text] [Related]
35. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial.
Distler O; Allanore Y; Denton CP; Kuwana M; Matucci-Cerinic M; Pope JE; Atsumi T; Bečvář R; Czirják L; Hachulla E; Ishii T; Ishikawa O; Johnson SR; De Langhe E; Stagnaro C; Riccieri V; Schiopu E; Silver RM; Smith V; Steen V; Stevens W; Szücs G; Truchetet ME; Wosnitza M; Laapas K; Kramer F; Khanna D
Lancet Rheumatol; 2023 Nov; 5(11):e660-e669. PubMed ID: 38251533
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
Khanna D; Clements PJ; Furst DE; Korn JH; Ellman M; Rothfield N; Wigley FM; Moreland LW; Silver R; Kim YH; Steen VD; Firestein GS; Kavanaugh AF; Weisman M; Mayes MD; Collier D; Csuka ME; Simms R; Merkel PA; Medsger TA; Sanders ME; Maranian P; Seibold JR;
Arthritis Rheum; 2009 Apr; 60(4):1102-11. PubMed ID: 19333948
[TBL] [Abstract][Full Text] [Related]
37. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
Khanna D; Denton CP; Jahreis A; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Lafyatis R; Stifano G; Spotswood H; Chen-Harris H; Dziadek S; Morimoto A; Sornasse T; Siegel J; Furst DE
Lancet; 2016 Jun; 387(10038):2630-2640. PubMed ID: 27156934
[TBL] [Abstract][Full Text] [Related]
39. High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.
Wannarong T; Muangchan C
Rheumatol Int; 2018 Dec; 38(12):2279-2288. PubMed ID: 30206672
[TBL] [Abstract][Full Text] [Related]
40. Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction () for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial.
Zhou J; Yang D; Zhou SH; Wang JP; Liu YS; Wang SL
Chin J Integr Med; 2018 Mar; 24(3):185-192. PubMed ID: 28197938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
